Cargando…

Cost-effectiveness of romosozumab for the treatment of postmenopausal women at very high risk of fracture in Canada

SUMMARY: This study evaluated the cost-effectiveness of 1 year of romosozumab followed by alendronate versus oral bisphosphonates alone in women with postmenopausal osteoporosis at very high risk for fracture in Canada. Results showed that romosozumab sequenced to alendronate is a cost-effective tre...

Descripción completa

Detalles Bibliográficos
Autores principales:	Goeree, Ron, Burke, Natasha, Jobin, Manon, Brown, Jacques P., Lawrence, Donna, Stollenwerk, Björn, Willems, Damon, Johnson, Ben
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer London 2022
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9042964/ https://www.ncbi.nlm.nih.gov/pubmed/35471711 http://dx.doi.org/10.1007/s11657-022-01106-9

Ejemplares similares

Cost-effectiveness of romosozumab for the treatment of postmenopausal women with severe osteoporosis at high risk of fracture in Sweden
por: Söreskog, E., et al.
Publicado: (2021)

Denosumab versus romosozumab for postmenopausal osteoporosis treatment
por: Kobayakawa, Tomonori, et al.
Publicado: (2021)

Economic burden of illness associated with diabetic foot ulcers in Canada
por: Hopkins, Robert B, et al.
Publicado: (2015)

Romosozumab for osteoporosis
Publicado: (2021)

The Effect of 1 Year of Romosozumab on the Incidence of Clinical Vertebral Fractures in Postmenopausal Women With Osteoporosis: Results From the FRAME Study
por: Geusens, Piet, et al.
Publicado: (2019)

Effects after starting or switching from bisphosphonate to romosozumab or denosumab in Japanese postmenopausal patients
por: Shimizu, Tomohiro, et al.
Publicado: (2021)

OR13-05 Romosozumab Treatment Lowers the Incidence of New Vertebral Fractures Across All Fracture Severity Grades Among Postmenopausal Women with Osteoporosis
por: Feldman, Robert, et al.
Publicado: (2020)

Romosozumab for the treatment of osteoporosis
por: McClung, Michael R.
Publicado: (2018)

Effect of Romosozumab on Trabecular Bone Score Compared to Anti-Resorptive Agents in Postmenopausal Women with Osteoporosis
por: Jeong, Chaiho, et al.
Publicado: (2021)

Efficacy and Safety of Romosozumab Among Postmenopausal Women With Osteoporosis and Mild‐to‐Moderate Chronic Kidney Disease
por: Miller, Paul D, et al.
Publicado: (2022)

Effect of Romosozumab on Trabecular Bone Score Compared to Anti-Resorptive Agents in Postmenopausal Women with Osteoporosis
por: Jeong, Chaiho, et al.
Publicado: (2022)

Real-world cost-effectiveness of denosumab for the treatment of postmenopausal osteoporosis in Taiwan
por: Johnson, Ben, et al.
Publicado: (2021)

Romosozumab and cardiovascular safety in Japan
por: Takeuchi, Yasuhiro
Publicado: (2021)

A Randomized, Placebo-Controlled Study of Romosozumab for the Treatment of Hip Fractures
por: Schemitsch, Emil H., et al.
Publicado: (2020)

Romosozumab improves lumbar spine bone mass and bone strength parameters relative to alendronate in postmenopausal women: results from the Active‐Controlled Fracture Study in Postmenopausal Women With Osteoporosis at High Risk (ARCH) trial
por: Brown, Jacques P., et al.
Publicado: (2021)

T‐Score as an Indicator of Fracture Risk During Treatment With Romosozumab or Alendronate in the ARCH Trial
por: Cosman, Felicia, et al.
Publicado: (2020)

Romosozumab in Postmenopausal Korean Women with Osteoporosis: A Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study
por: Baek, Ki-Hyun, et al.
Publicado: (2021)

Romosozumab in osteoporosis: yesterday, today and tomorrow
por: Wu, Dong, et al.
Publicado: (2023)

Skeletal responses to romosozumab after 12 months of denosumab
por: McClung, Michael R., et al.
Publicado: (2021)

Risk of falls in postmenopausal women treated with romosozumab: Preliminary indices from a meta-analysis of randomized, controlled trials
por: Möckel, Luis, et al.
Publicado: (2020)

Bone‐Forming and Antiresorptive Effects of Romosozumab in Postmenopausal Women With Osteoporosis: Bone Histomorphometry and Microcomputed Tomography Analysis After 2 and 12 Months of Treatment
por: Chavassieux, Pascale, et al.
Publicado: (2019)

The effects of romosozumab combined with active vitamin D(3) on fracture healing in ovariectomized rats
por: Takase, Ryota, et al.
Publicado: (2022)

Cost-Effectiveness Analysis of Evolocumab in Adult Patients with Atherosclerotic Cardiovascular Disease in Canada
por: Grégoire, Jean, et al.
Publicado: (2022)

Cost-effectiveness of ticagrelor versus clopidogrel in patients with acute coronary syndromes in Canada
por: Grima, Daniel T, et al.
Publicado: (2014)

Profile of romosozumab and its potential in the management of osteoporosis
por: Lim, Sian Yik, et al.
Publicado: (2017)

Romosozumab and antiresorptive treatment: the importance of treatment sequence
por: Cosman, Felicia, et al.
Publicado: (2022)

Romosozumab versus Teriparatide for the Treatment of Postmenopausal Osteoporosis: A Systematic Review and Meta‐analysis through a Grade Analysis of Evidence
por: Tian, Aixian, et al.
Publicado: (2021)

Impact of romosozumab on serum calcium concentration and factors predicting the fluctuations in calcium concentration upon romosozumab administration: A multicenter retrospective study
por: Inose, Hiroyuki, et al.
Publicado: (2022)

Cost-effectiveness analysis of intranasal live attenuated vaccine (LAIV) versus injectable inactivated influenza vaccine (TIV) for Canadian children and adolescents
por: Tarride, Jean-Eric, et al.
Publicado: (2012)

Romosozumab-aqqg in the Treatment of Osteoporosis in a Patient With Hypophosphatasia
por: Khanjee, Naveed, et al.
Publicado: (2022)

MON-378 Efficacy and Safety of Romosozumab vs Alendronate Is Similar Across Different Levels of Renal Function Among Postmenopausal Women with Osteoporosis
por: Miller, Paul, et al.
Publicado: (2020)

Romosozumab Enhances Vertebral Bone Structure in Women With Low Bone Density
por: Poole, Kenneth ES, et al.
Publicado: (2021)

Romosozumab improves low bone mineral density in a postmenopausal woman undergoing chronic hemodialysis and treated with a calcium-sensing receptor agonist
por: Ogata, Masatomo, et al.
Publicado: (2022)

OR13-06 Romosozumab After Denosumab Improves Lumbar Spine Bone Mineral Density And Microarchitecture Greater Than Denosumab Continuation In Postmenopausal Women
por: Hong, Namki, et al.
Publicado: (2023)

Romosozumab, clinical trials, and real-world care of patients with osteoporosis
por: Lewiecki, E. Michael
Publicado: (2020)

Romosozumab: a novel bone anabolic treatment option for osteoporosis?
por: Kerschan-Schindl, Katharina
Publicado: (2019)

Romosozumab for the treatment of osteoporosis in women: Efficacy, safety, and cardiovascular risk
por: Lim, Sian Yik
Publicado: (2022)

Romosozumab efficacy and safety in European patients enrolled in the FRAME trial
por: Langdahl, Bente, et al.
Publicado: (2022)

Vitiligo progression in a patient undergoing romosozumab treatment for osteoporosis
por: Trepanowski, Nicole, et al.
Publicado: (2023)

Romosozumab was not effective in preventing multiple spontaneous clinical vertebral fractures after denosumab discontinuation: A case report
por: Kashii, Masafumi, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_iosbbcggnafdesqectmru7bb4n